glp-1 for weight loss pills Wegovy Pill Wins FDA Approval as First Oral Treatment Obesity and reduce hunger Novo Nordisk launches Wegovy weight-loss

One study published in 2025 in Diabetologia looked at whether taking GLP-1 drugs were associated with worsening of retinopathy when patients had no or only mild nonproliferative diabetic retinopathy (NPDR) at initiation of treatment

A 2023 review of 254 studies concluded that benzophenone-3 (a.k.a

Alcohol consumption can affect glycemic control, and the combination of GLP-1 therapy with alcohol might increase hypoglycemia risk, particularly in patients taking concomitant insulin or sulfonylureas

Trans Res

The authors recommend weight-based (lean body weight) dose calculation, reducing concentration as volume increases, incremental injection with aspiration, close post-block monitoring, and routine consideration of low-dose epinephrine to blunt peak plasma levels